BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18544953)

  • 21. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of staging systems to predict survival in hepatocellular carcinoma.
    Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
    Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.
    Hsu CY; Huang YH; Hsia CY; Su CW; Lin HC; Loong CC; Chiou YY; Chiang JH; Lee PC; Huo TI; Lee SD
    J Hepatol; 2010 Jul; 53(1):108-17. PubMed ID: 20451283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy.
    Seong J; Shim SJ; Lee IJ; Han KH; Chon CY; Ahn SH
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1037-42. PubMed ID: 17234356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey.
    Huo TI; Lin HC; Hsia CY; Wu JC; Lee PC; Chi CW; Lee SD
    Am J Gastroenterol; 2007 Sep; 102(9):1920-30. PubMed ID: 17573792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival.
    Kiriyama S; Uchiyama K; Ueno M; Ozawa S; Hayami S; Tani M; Yamaue H
    Ann Surg; 2011 Dec; 254(6):984-91. PubMed ID: 21606837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
    Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
    Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma.
    Aoyagi Y; Isokawa O; Suda T; Watanabe M; Suzuki Y; Asakura H
    Cancer; 1998 Nov; 83(10):2076-82. PubMed ID: 9827711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
    Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
    Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
    Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
    Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
    Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
    Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The challenge of prognosis and staging for hepatocellular carcinoma.
    Marrero JA; Kudo M; Bronowicki JP
    Oncologist; 2010; 15 Suppl 4():23-33. PubMed ID: 21115578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.
    Tateishi R; Yoshida H; Shiina S; Imamura H; Hasegawa K; Teratani T; Obi S; Sato S; Koike Y; Fujishima T; Makuuchi M; Omata M
    Gut; 2005 Mar; 54(3):419-25. PubMed ID: 15710994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
    Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
    J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy.
    Chen TW; Chu CM; Yu JC; Chen CJ; Chan DC; Liu YC; Hsieh CB
    Eur J Surg Oncol; 2007 May; 33(4):480-7. PubMed ID: 17129701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy.
    Nanashima A; Omagari K; Sumida Y; Abo T; Fukuoha H; Takeshita H; Hidaka S; Tanaka K; Sawai T; Yasutake T; Nagayasu T; Mizuta Y; Ohba K; Ohnita K; Kadokawa Y
    Hepatogastroenterology; 2009; 56(93):1137-40. PubMed ID: 19760957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.